Insights
Search Results
Client Highlights
6.10.26
Wilson Sonsini Advises SonoThera on Patent Matters Related to Oversubscribed $125 Million Series B
On June 10, 2026, SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines. Wilson Sonsini Goodrich & Rosati advised SonoThera on patent matters related to the transaction.
Client Highlights
9.03.25
Wilson Sonsini Advises Galvanize Therapeutics on $100 Million Series C Financing
On September 3, 2025, Galvanize Therapeutics, Inc., a commercial-stage medical technology company pioneering pulsed electric field (PEF) therapies for oncology and chronic lung disease, announced that it has raised $100 million in an oversubscribed Series C financing. The round was led by Sofinnova Partners, with participation from a global syndicate of top-tier investors including Norwest Venture Partners, Elevage Medical Technologies, Ally Bridge Group, Perceptive Xontogeny Venture Fund, Janus Henderson Investors, and Longaeva. Existing investors Fidelity Management & Research Company, T. Rowe Price, Gilmartin Capital, Intuitive Surgical, and Apple Tree Partners (ATP), the company's founding investor, also participated in the round. Wilson Sonsini Goodrich & Rosati advised Galvanize on the transaction. The proceeds from the financing will be used to expand the company's commercial footprint and advance its clinical and development activities related to Aliya® PEF in solid tumors and RheOx® therapy for chronic bronchitis.
The Wilson Sonsini team that advised Galvanize on the transaction included:
The Wilson Sonsini team that advised Galvanize on the transaction included:
Client Highlights
7.02.25
Firm Advises Matterworks on IP and Patent Matters Related to Series A Financing
On June 3, 2025, Matterworks, Inc., the category-defining pioneer unlocking unstructured molecular data for predictive biology, announced a new Series A financing. The round was led by Lewis & Clark Partners and OMX Ventures and joined by Pillar VC, Germin8 Ventures, Intermountain Ventures, and Tarsadia, among others. Matterworks will use the Series A proceeds to grow its model as a service (MaaS) business and expand its machine learning and scientific operations. For example, Matterworks' Large Spectral Models (LSMs) productize self-supervised machine intelligence for direct machine interpretation of molecular-omic data. The company’s PyxisTMproduct, released in 2024, is the first generative AI for complete untargeted molecular annotation, unlocking new data modalities for understanding and predicting complex biological outcomes.
Client Highlights
7.24.24
Wilson Sonsini Advises Novo Holdings in Magenta Medical’s $105 Million Financing
On July 23, 2024, Novo Holdings, a leading life science investor, announced that it has led a $105 million financing in Magenta Medical, developer of the Elevate™ System, the world's smallest heart pump.
Client Highlights
5.20.24
Wilson Sonsini Advises Novo Holdings on IP Matters Related to Majority Stake in Single Use Support
On May 15, 2024, Novo Holdings A/S (Novo Holdings) announced the acquisition of a majority stake in Austria-based Single Use Support, a fast-growing life science tools company providing advanced technology solutions for the pharmaceutical production process. Wilson Sonsini Goodrich & Rosati advised Novo Holdings on IP Matters related to the transaction.
Client Highlights
3.21.24
Wilson Sonsini Advises LENZ Therapeutics on Completed Merger with Graphite Bio
On March 21, 2024, LENZ Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, announced the completion of its previously announced merger with Graphite Bio, Inc. The new combined company will operate under the name LENZ Therapeutics, Inc. and will commence trading on Nasdaq under the ticker symbol “LENZ” on March 22, 2024. Wilson Sonsini Goodrich & Rosati advised LENZ Therapeutics on the transaction.
Client Highlights
8.29.23
Wilson Sonsini Represents Thorne HealthTech in Sale to L Catterton
On August 28, 2023, Thorne HealthTech, Inc., a leader in delivering innovative solutions for a personalized approach to health and wellness, announced that it has entered into a definitive agreement under which L Catterton, a leading global consumer-focused investment firm, will commence a tender offer to acquire all outstanding shares of common stock of Thorne for $10.20 per share in cash. The transaction value of approximately $680 million represents a 94 percent premium to the unaffected closing share price on July 20, 2023, and a 113 percent premium to the 30-day volume weighted average price as of the unaffected date of July 20, 2023. Thorne's independent Special Committee and board of directors have each unanimously approved the agreement and recommend that Thorne’s stockholders tender their shares into the tender offer. Wilson Sonsini Goodrich & Rosati represented Thorne and the Special Committee of the board of directors in the transaction.
The transaction is expected to be completed in the fourth quarter of 2023, subject to customary closing conditions. Subject to the terms and conditions of the agreement, following the completion of the tender offer, L Catterton will acquire any shares of Thorne that are not tendered in the tender offer through a second-step merger for $10.20 per share in cash. Upon completion of the transaction, Thorne will become a privately held company and its shares of common stock will no longer be listed on any public market.
The Wilson Sonsini team that represented Thorne and the Special Committee of the board of directors includes:
The transaction is expected to be completed in the fourth quarter of 2023, subject to customary closing conditions. Subject to the terms and conditions of the agreement, following the completion of the tender offer, L Catterton will acquire any shares of Thorne that are not tendered in the tender offer through a second-step merger for $10.20 per share in cash. Upon completion of the transaction, Thorne will become a privately held company and its shares of common stock will no longer be listed on any public market.
The Wilson Sonsini team that represented Thorne and the Special Committee of the board of directors includes:
Newsletters
7.27.23
Sustainability and ESG Advisory Practice Update, July 2023
We are pleased to share the July 2023 issue of Wilson Sonsini's Sustainability and ESG Advisory Practice Update. Each issue combines news, key legal developments, and resources related to sustainability and environmental, social, and governance (ESG) matters relevant to public and private companies internationally.
Client Highlights
9.13.22
Wilson Sonsini Advises Good Therapeutics on IP Matters Related to Acquisition by Roche
On September 7, 2022, Good Therapeutics, a privately held company founded to create a new class of conditionally active therapeutics, announced it has entered into a definitive merger agreement to be acquired by Roche. With this acquisition, Roche will gain rights to Good Therapeutics’ innovative, conditionally active, PD-1-regulated IL-2 program and an exclusive right to the platform technology for the development of PD-1-regulated IL-2 receptor agonist therapeutics. Wilson Sonsini Goodrich & Rosati advised Good Therapeutics on IP matters related to the transaction.